A major breakthrough!

On June 10 , according to the official website of China National Medical Products Administration ( NMPA ), the approval document for the new indication drug for colorectal cancer of Pembrolizumab (commonly known as "K drug " in China ) was already in the waiting state

On June 10 , according to the official website of China National Medical Products Administration ( NMPA ), Pembrolizumab (commonly known as Pembrolizumab in China (commonly known as "K drug " and "K drug " ) is a new indication for colorectal cancer The drug approval certificate is already in the waiting state

It is reported that the application for the K drug for this indication is based on the phase III clinical study KEYNOTE-177 .

It is noteworthy that, in the just-concluded annual meeting of the American Society of Clinical Oncology ( ASCO on), KEYNOTE-177 study announced the final results of the analysis showed that for for MSI-H / dMMR metastatic or unresectable of colorectal cancer For patients, the immunotherapeutic drug pembrolizumab as a first-line treatment is far superior to traditional chemotherapy regimens in efficacy and safety, and at the same time meets the goals of long-term effectiveness, precision and safety

The incidence of colorectal cancer in China is on the rise, and the prognosis of certain advanced patients is poor.

With the acceleration of China's urbanization process and the improvement of residents' living standards in recent years, the number of intestinal cancer cases in China has also shown a significant upward trend, ranking second in overall cancer incidence and first in gastrointestinal cancer incidence

At the same time, many patients with bowel cancer are already in the middle-advanced stage when they are diagnosed, and the prognosis is not good.

Colorectal cancer treatment has entered the era of precision immunization, and people who can accurately benefit from detection and screening.

The emergence of immunotherapy has brought a turning point for patients with MSI-H/dMMR advanced colorectal cancer

According to ASCO 2021 latest annual meeting KEYNOTE-177 results of the study, for against MSI-H / dMMR advanced colorectal cancer patients, Pa Boli natalizumab monotherapy first-line therapy compared to conventional chemotherapy, not only can be achieved The median progression-free survival is doubled ( 16.

As early as 2017 , the U.

Now, with KEYNOTE-177 research data, pembrolizumab is officially approved for colorectal cancer indications in China, leading the domestic colorectal cancer treatment to open the era of precision immunization, so that patients with MSI-H/dMMR advanced colorectal cancer can maximize the benefits
.
China is a big country with gastrointestinal tumors.
It is believed that the approval of pembrolizumab will hopefully enable colon cancer patients to achieve long-term survival and even " cure " goals
.


Leave a message here